Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
changjianhua
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
NR
Planned for methodology v0.2.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| R-Star001 (this asset) | changjianhua | P1 | CCC · 53 |
| Nabiximols | Jazz Pharmaceuticals | P3 | A |
| Fentanyl | M.D. Anderson Cancer Center | P3 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BBB |
| Etoposide | EMD Serono Research & Development Institute, Inc. | P3 | BBB |
| Testosterone Undecylate | Aminex Therapeutics, Inc. | P3 | BBB |
| Capecitabine | University of Alabama at Birmingham | P3 | BBB |
| Vinorelbine Ditartrate | University Health Network, Toronto | P3 | BBB |
| Ipilimumab | 7 Hills Pharma, LLC | P2 | BBB |
+42 more in the Cancer cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. R-Star001 in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 15, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/r-star001-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →